Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD

被引:340
作者
Kuriyan, Ajay E. [1 ,3 ]
Albini, Thomas A. [1 ]
Townsend, Justin H. [1 ]
Rodriguez, Marianeli [1 ]
Pandya, Hemang K. [4 ]
Leonard, Robert E., II [4 ]
Parrott, M. Brandon [2 ]
Rosenfeld, Philip J. [1 ]
Flynn, Harry W., Jr. [1 ]
Goldberg, Jeffrey L. [5 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA
[2] Ctr Sight, Sarasota, FL USA
[3] Univ Rochester, Med Ctr, Dept Ophthalmol, Flaum Eye Inst, Rochester, NY 14642 USA
[4] Univ Oklahoma, Dept Ophthalmol, Dean McGee Eye Inst, Oklahoma City, OK USA
[5] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA
基金
美国国家卫生研究院;
关键词
IN-VITRO DIFFERENTIATION; OPTIC-NERVE DISEASES; MACULAR DEGENERATION; OPHTHALMOLOGY TREATMENT; CLINICS; INTERVENTIONS; FDA; THERAPIES; SCOTS;
D O I
10.1056/NEJMoa1609583
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adipose tissue-derived "stem cells"have been increasingly used by "stem-cell clinics" in the United States and elsewhere to treat a variety of disorders. We evaluated three patients in whom severe bilateral visual loss developed after they received intravitreal injections of autologous adipose tissue-derived "stem cells"at one such clinic in the United States. In these three patients, the last documented visual acuity on the Snellen eye chart before the injection ranged from 20/30 to 20/200. The patients' severe visual loss after the injection was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenous retinal detachment, or lens dislocation. After 1 year, the patients' visual acuity ranged from 20/200 to no light perception.
引用
收藏
页码:1047 / 1053
页数:7
相关论文
共 24 条
[1]   Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies [J].
Ambati, J ;
Ambati, BK ;
Yoo, SH ;
Ianchulev, S ;
Adamis, AP .
SURVEY OF OPHTHALMOLOGY, 2003, 48 (03) :257-293
[2]   Responsibilities of Health Care Professionals in Counseling and Educating PatientsWith Incurable Neurological Diseases Regarding "Stem Cell Tourism" Caveat Emptor [J].
Bowman, Michelle ;
Racke, Michael ;
Kissel, John ;
Imitola, Jaime .
JAMA NEUROLOGY, 2015, 72 (11) :1342-1345
[3]   Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature [J].
Falavarjani, K. Ghasemi ;
Nguyen, Q. D. .
EYE, 2013, 27 (07) :787-794
[4]  
Francis PJ, 2010, INVEST OPHTH VIS SCI, V51
[5]  
Ho AC, 2015, ANG EX DEG 2015 C MI
[6]   A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss - AREDS Report No. 8 [J].
Kassoff, A ;
Kassoff, J ;
Buehler, J ;
Eglow, M ;
Kaufman, F ;
Mehu, M ;
Kieval, S ;
Mairs, M ;
Graig, B ;
Quattrocchi, A ;
Jones, D ;
Locatelli, J ;
Ruby, A ;
Capone, A ;
Garretson, B ;
Hassan, T ;
Trese, MT ;
Williams, GA ;
Regan, V ;
Manatrey, P ;
Streasick, P ;
Szydlowski, L ;
McIver, F ;
Bridges, C ;
Stanley, C ;
Cumming, K ;
Lewis, B ;
Zajechowski, M ;
Margherio, RR ;
Cox, MS ;
Camille, J ;
Falk, R ;
Siedlak, P ;
Neubert, C ;
Klein, ML ;
Stout, JT ;
O'Malley, A ;
Lauer, AK ;
Robertson, JE ;
Wilson, DJ ;
Beardsley, C ;
Anderson, H ;
Wallace, P ;
Smith, G ;
Howard, S ;
Dreyer, RF ;
Ma, C ;
Chenoweth, RG ;
Zilis, JD ;
Johnson, M .
ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (10) :1417-1436
[7]  
KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
[8]   From bench to FDA to bedside: US regulatory trends for new stem cell therapies [J].
Knoepfler, Paul S. .
ADVANCED DRUG DELIVERY REVIEWS, 2015, 82-83 :192-196
[9]   Sources of retinal pigment epithelium (RPE) for replacement therapy [J].
Lee, E. ;
MacLaren, R. E. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2011, 95 (04) :445-449
[10]   In vitro Differentiation of Adult Adipose Mesenchymal Stem Cells into Retinal Progenitor Cells [J].
Moviglia, Gustavo A. ;
Blasetti, Nahuel ;
Zarate, Jorge O. ;
Pelayes, David E. .
OPHTHALMIC RESEARCH, 2012, 48 :1-5